A detailed history of Cwm, LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Cwm, LLC holds 108 shares of CVAC stock, worth $309. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108
Previous 108 -0.0%
Holding current value
$309
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

SELL
$2.31 - $4.99 $173 - $374
-75 Reduced 40.98%
108 $0
Q3 2022

Oct 27, 2022

SELL
$7.48 - $15.24 $291 - $594
-39 Reduced 17.57%
183 $1,000
Q2 2022

Jul 28, 2022

SELL
$13.18 - $19.41 $79 - $116
-6 Reduced 2.63%
222 $3,000
Q1 2022

Apr 21, 2022

BUY
$14.73 - $35.25 $662 - $1,586
45 Added 24.59%
228 $4,000
Q4 2021

Jan 31, 2022

BUY
$33.72 - $48.22 $2,529 - $3,616
75 Added 69.44%
183 $6,000
Q4 2020

Sep 15, 2021

BUY
$46.76 - $136.27 $5,050 - $14,717
108 New
108 $8,000
Q4 2020

Jan 27, 2021

SELL
$46.76 - $136.27 $5,050 - $14,717
-108 Closed
0 $0
Q3 2020

Sep 15, 2021

BUY
$43.8 - $77.2 $4,730 - $8,337
108 New
108 $8,000
Q3 2020

Oct 19, 2020

SELL
$43.8 - $77.2 $4,730 - $8,337
-108 Closed
0 $0
Q2 2020

Sep 15, 2021

BUY
N/A
108 New
108 $8,000
Q2 2020

Jul 22, 2020

SELL
N/A
-108 Closed
0 $0
Q1 2020

Sep 15, 2021

BUY
N/A
108 New
108 $8,000
Q1 2020

Apr 28, 2020

SELL
N/A
-108 Closed
0 $0
Q4 2019

Sep 14, 2021

BUY
N/A
108 New
108 $8,000
Q4 2019

Jan 27, 2020

SELL
N/A
-108 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
N/A
108 New
108 $8,000
Q3 2019

Oct 22, 2019

SELL
N/A
-108 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
N/A
108 New
108 $8,000
Q2 2019

Jul 31, 2019

SELL
N/A
-108 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
N/A
108 New
108 $0

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $538M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.